A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.

Completed · Phase 2

Conditions studied: Breast Neoplasms

In brief

Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.

Key facts

Study ID

NCT00078000

Run by

Pfizer

People needed

64

Starts

2004-03-01

Expected to finish

2005-11-01

Last updated by the study team

2008-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Anthracycline and taxane-refractory or intolerant metastatic breast cancer
• Female

You may not qualify if…

• Prior treatment with 3 or greater regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines/taxanes.

Where it is running

• Pfizer Investigational Site — Greenbrae, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.